The FDA has approved an application to initiate a pilot study with Alpha DaRT for patients with recurrent glioblastoma, a ...
Despite decades of research to develop effective treatments, the median survival for glioblastoma—the most common malignant ...
The former lawmaker from Utah had undergone treatment for glioblastoma, a malignant brain tumor, and received immunotherapy ...
Researchers at The University of Texas Health Science Center at San Antonio have discovered a way to delay or even block ...
The phase 2 GIANT trial will evaluate Opdivo with or without relatlimab in IDH-wildtype newly diagnosed glioblastoma.
Early results show that the combination of VXM01 plus avelumab demonstrated tolerable safety in recurrent glioblastoma.
Love, who represented Utah, had been battling glioblastoma, a malignant brain tumor. She had received immunotherapy treatment as part of a clinical trial, but her daughter revealed earlier this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback